Latest News - Retina

Friday, October 14, 2016 | Retina, Novartis

Lucentis Recommended by CHMP for EU Approval in Sixth Indication for the Treatment of Visually Impaired Patients

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal ne…

Read the full story

Friday, October 14, 2016 | Retina

Spark Therapeutics Launches Initiative to Improve Access to Genetic Testing for Inherited Retinal Diseases

Spark Therapeutics will provide physicians and eligible patients access to genetic testing and counseling for more than 30 genes linked to certain forms of inherited retinal diseases (IRDs), a group o…

Read the full story

Thursday, October 13, 2016 | Partnerships, Retina, Ocular Therapeutix, Regeneron Pharmaceuticals

Ocular Therapeutix and Regeneron Collaborate to Develop a Sustained-Release Formulation of Aflibercept for Wet AMD and Other Retinal Diseases

In a deal that could be worth more than $300 million, Ocular Therapeutix announced that it has entered into a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals to c…

Read the full story

Thursday, October 13, 2016 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2B Trial Evaluating Luminate in Patients with Diabetic Macular Edema

Allegro Ophthalmics announced that the DEL MAR phase 2b clinical trial evaluating Luminate (ALG-1001) in 136 patients with diabetic macular edema (DME) met its primary and secondary endpoints, demonst…

Read the full story

Thursday, October 13, 2016 | Retina

Retinal Consultants of Arizona Opens Largest, Most Advanced Clinical, Surgical & Retina Research Institute in Phoenix

Retinal Consultants of Arizona (RCA), one of the nation’s leading Retina & Vitreous clinical research and patient treatment facilities, announced the opening of a 35,000 sqaure-foot clinical…

Read the full story

Tuesday, October 11, 2016 | Conferences, Retina

Retina World Congress Releases Full Meeting Agenda

Retina World Congress, a collaboration of international retina societies, announced the publication of its preliminary full agenda for the inaugural meeting to be held February 23-26, 2017, at the Mar…

Read the full story

Tuesday, October 11, 2016 | Clinical Trials, Retina, Genentech

FDA Grants Priority Review to Genentech’s Lucentis Supplemental Biologics License Application for Myopic Choroidal Neovascularization

Genentech announced that the FDA has accepted a supplemental Biologics License Application (sBLA) and granted priority review for Lucentis (ranibizumab) for the treatment of myopic choroidal neovascul…

Read the full story

Monday, October 03, 2016 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate for Non-Proliferative Diabetic Retinopathy

Allegro Ophthalmics announced completion of enrollment in its PACIFIC phase 2b clinical trial that is evaluating the safety and efficacy of Luminate (ALG-1001) in inducing posterior vitreous detachmen…

Read the full story

Friday, September 30, 2016 | Clinical Trials, Retina, Regeneron Pharmaceuticals

Combination Therapy Shows No Benefit Over Aflibercept Alone in Phase 2 AMD Trial

The phase 2 CAPELLA study evaluating aflibercept (Eylea, Regeneron) coformulated with rinucumab (Regeneron), an anti-platelet-derived growth factor (anti-PDGF) receptor beta antibody, in patients with…

Read the full story

Wednesday, September 28, 2016 | Product Releases, Retina

Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal Diseases

Cellular Dynamics International, a FUJIFILM company and a developer and manufacturer of induced pluripotent stem cell (iPSC) products, announced a new venture, named Opsis Therapeutics. Formed on July…

Read the full story

Tuesday, September 06, 2016 | Product Releases, Retina, SalutarisMD

SalutarisMD to Introduce its New Generation Medical Device for wet AMD Therapy at Ophthalmology Futures European Forum

Salutaris Medical Devices announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the company will introduce its new generation, commercial ready, e…

Read the full story

Friday, August 12, 2016 | Retina

Real-World Anti-VEGF Data Disappointing

The reality of antivascular endothelial growth factor (anti-VEGF) treatments for neovascular age-related macular degeneration seen in US ophthalmology practices falls far short of the promise of clini…

Read the full story

Thursday, August 11, 2016 | Retina

Genes May Shape Supplements' Effect on Macular Degeneration

A person's genotypes may influence whether or not nutritional supplements help or hinder the progress of age-related macular degeneration, according to the results of two new studies. The studi…

Read the full story

Thursday, August 11, 2016 | Retina

American Society of Retina Specialists and SAGE Publishing Launch Journal of VitreoRetinal Diseases

The American Society of Retina Specialists (ASRS) and SAGE Publishing announced the launch of the Journal of VitreoRetinal Diseases (JVRD). The new journal will provide unparalleled coverage of the ra…

Read the full story

Monday, August 08, 2016 | Clinical Trials, Retina, ThromboGenics

ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology

ThromboGenics announced that the results from its 2 Year OASIS phase 3b study with Jetrea (ocriplasmin) have been published in the journal Ophthalmology. The OASIS study was a phase 3b randomized, …

Read the full story
Load More